Value-Based Care Models

Value-based care (VBC) models represent a fundamental restructuring of healthcare reimbursement, shifting from volume-based fee-for-service to payment systems that reward quality, outcomes, and cost efficiency. Also known as value-based purchasing, alternative payment models (APMs), or outcomes-based reimbursement, these models tie provider payments to measured performance on quality metrics and total cost of care.

Classification of Value-Based Care Models

Several distinct models exist, each with a unique payment mechanism and organizational structure. The main types are summarized in the table below.

The choice of model depends on the clinical context, patient population, and organizational readiness. For example, bundled payments are common for elective surgical episodes, while ACOs are used for comprehensive population management .

Clinical and Economic Significance

The push toward VBC is driven by the recognition that the US healthcare system spends more per capita than any other developed nation yet achieves inferior outcomes on several measures. Early evidence suggests that VBC models can reduce spending without harming quality. For instance, studies on distal radius fracture repair show that even as patient comorbidities have worsened, rates of readmission and revision surgery have declined under value-based care transitions ^[1]B2b. Similarly, in metastatic pancreatic cancer, total cost of care is 186% higher for commercially insured patients than Medicare patients, yet treatment patterns are largely consistent, highlighting opportunities for cost standardization under value-based arrangements ^[2]B2b.

Pearl: The defining feature of all VBC models is that provider financial risk is proportional to the degree of accountability for patient outcomes, the more risk assumed, the greater the potential reward (and penalty) for quality and cost performance.

From the definitional framework of value-based care, the core pathogenetic mechanism is the realignment of financial incentives away from volume and toward outcomes. This section traces the causal chain through which payment reform, cost measurement, and care coordination produce changes in provider behavior and patient outcomes.

The Incentive Structure

At the heart of value-based models lies a fundamental shift: providers assume financial risk for the total cost and quality of care over a defined episode or population. In an accountable care organization (ACO), for example, participating entities share in savings generated when actual spending falls below a budgeted target, provided quality benchmarks are met ^[4]C4. This risk-bearing mechanism creates a direct economic pressure to reduce unnecessary utilization, fewer redundant tests, lower readmission rates, and shorter hospital stays, while simultaneously improving processes that affect quality scores. The result is a self-reinforcing loop: better outcomes reduce cost, which increases shared savings, which funds further quality investments.

Cost-Accounting as a Mechanism

Accurate cost measurement is the engine that makes value-based contracts operational. Time-driven activity-based costing (TDABC) has emerged as a robust method for detecting variability in resource use across care episodes. In spine surgery, TDABC analyses revealed that total cost estimates range from $201.78 per patient for a multidisciplinary conference to $30,566 for a 2-level anterior cervical discectomy and fusion ^[3]B2a. The key cost drivers identified, case volume, number of levels fused, intraoperative magnification, patient BMI, discharge timing, and screw navigation methods, represent modifiable targets that value-based interventions can address. TDABC thus serves as the costing denominator in a proposed enabling technology value index, linking cost to outcome in a reproducible fashion ^[3]B2a.

Care Coordination Integration

Value-based models also operate through structural mechanisms that bridge fragmented care. The integration of medication therapy management (MTM) services provided by community pharmacists into ACO clinical teams exemplifies this pathway. In a twelve-county Minnesota ACO, collaborating with 15 community pharmacies via Direct Secure Messaging enabled electronic referrals for MTM; over one year, 32 patients received MTM services subsequent to ACO referrals ^[4]C4. This mechanism reduces adverse drug events, improves medication adherence, and decreases downstream spending, each step traceable to the underlying payment incentive that rewards cost-effective, coordinated care.

The sequence is therefore: (1) financial risk assumption alters provider priorities; (2) cost-accounting tools (TDABC) identify high-variability cost drivers; (3) quality measurement scores guide improvement efforts; (4) care coordination (MTM, multidisciplinary conferences) reduces waste and complications; (5) shared savings or bundled payments complete the feedback loop, reinforcing the cycle. Every clinical feature described in later sections, from reduced complication rates in multidisciplinary conferences to lower total episode costs, can be traced back to this economic and organizational pathophysiology.

Pearl: Integration of care coordination services, such as medication therapy management, reduces waste and improves outcomes through aligned payment structures.

The adoption of value-based care models (VBCMs) has accelerated over the past decade, driven by the shift from fee-for-service to outcome-based reimbursement. However, the prevalence of VBCM implementation across healthcare systems remains uneven, and performance within these models is influenced by a complex interplay of patient, provider, and system-level factors.

Prevalence and Demographic Distribution

Nationally, federally qualified health centers (FQHCs), which serve 26.6 million patients (63% aged 18-64 years, 56% female), represent a key testing ground for VBCM ^[11]B2b. Among elective surgical procedures, 45.6% of esophagectomies are performed at high-volume hospitals (≥20 cases/year), a volume threshold linked to superior outcomes under VBCM ^[12]B2b. In orthopedic surgery, a cohort of 4,324 patients undergoing total knee arthroplasty (TKA) provided granular data on factors influencing quality metric achievement ^[7]B2b.

Temporal Trends

During the COVID-19 pandemic, nearly all quality-of-care measures at FQHCs declined sharply. Between 2019 and 2020, cervical cancer screening dropped -3.8 percentage points (pp) (95% CI, -4.3 to -3.2 pp), depression screening fell -7.0 pp (95% CI, -8.0 to -5.9 pp), and blood pressure control in hypertensive patients decreased -6.5 pp (95% CI, -7.0 to -6.0 pp) ^[11]B2b. By 2021, only 1 of 10 declined measures returned to prepandemic levels. Visit volumes for immunizations, oral examinations, and child health supervision declined significantly (incidence rate ratios [IRR] of 0.76, 0.61, and 0.87, respectively) and 60% of these remained below baseline in 2021 ^[11]B2b. Conversely, mental health and substance use disorder visits increased, depression (IRR 1.06), anxiety (IRR 1.16), and substance use disorder (IRR 1.07), and continued rising through 2021 ^[11]B2b. These trends suggest that VBCM performance metrics are vulnerable to external shocks and that behavioral health needs may be increasingly captured under VBCM frameworks.

Risk Factors for Poor Performance Under VBCM

Achievement of quality thresholds in VBCM is partly determined by modifiable perioperative factors. In TKA, bilateral procedures were associated with higher odds of achieving the Knee Injury and Osteoarthritis Outcome Score (KOOS) minimal clinically important difference (MCID) (OR 2.60, P<0.001) and patient acceptable symptom state (PASS) (OR 2.4, P≤0.001) ^[7]B2b. Conversely, longer length of stay (LOS) was inversely associated with KOOS MCID (OR 0.88, P=0.002) and PASS (OR 0.81, P<0.001), but directly associated with home discharge (OR 2.5, P≤0.001), in-hospital complications (OR 1.50, P<0.001), and 90-day readmissions (OR 1.23, P=0.005) ^[7]B2b. Tranexamic acid (TXA) use improved KOOS MCID (OR 1.33, P=0.008) and PASS (OR 1.29, P=0.020), while aspirin thromboprophylaxis reduced the odds of achieving these metrics (OR 0.68 and 0.73, respectively) ^[7]B2b. In-hospital opioid use was an independent risk factor for not achieving SF-12 mental component summary MCID (OR 0.56, P=0.006) ^[7]B2b.

At the system level, hospital esophagectomy volume is a critical non-modifiable factor. Compared with low-volume hospitals (<20 cases/year), high-volume hospitals (≥20/year) had lower adjusted odds of in-hospital mortality (AOR 0.65), pneumonia (AOR 0.69), prolonged ventilation (AOR 0.50), and sepsis (AOR 0.80), with no increase in costs ^[12]B2b. These findings support centralization of complex procedures as congruent with VBCM.

Risk Factor Table for Achieving Quality Metrics Under VBCM

Pearl: Modifiable perioperative factors, particularly TXA use, avoidance of aspirin thromboprophylaxis, and minimizing opioid use, significantly influence achievement of VBCM quality thresholds and should be targeted in preoperative optimization protocols.

Presenting Symptoms: The VBC Patient Profile

The patient who enters a value-based care model often does so through a recognizable clinical pattern: an older adult with multiple chronic conditions, discharged from an acute hospitalization to a post-acute care facility. Over 40% of patients follow this trajectory, and these transitions are frequently siloed, creating care gaps that manifest as symptom exacerbation, functional decline, or early readmission ^[13]D5. The generalist should suspect VBC involvement when a patient presents with poorly controlled diabetes, hypertension , or heart failure despite standard therapy, or when a surgical patient reports persistent pain or limited mobility weeks after a procedure. These are the patients for whom the model's incentives, prevention, coordination, and outcome tracking, are most relevant.

Clinical Examination: Metrics as Vital Signs

In VBC, the "examination" extends beyond the physical to include patient-reported outcome measures (PROMs) and modifiable perioperative factors. For total knee arthroplasty (TKA), the Knee Injury and Osteoarthritis Outcome Score (KOOS) and Short Form-12 (SF-12) serve as functional and quality-of-life benchmarks. Achievement of the minimal clinically important difference (MCID) and patient acceptable symptom state (PASS) are key thresholds. Several surgeon-influenced factors predict these outcomes:

These data, derived from a cohort of 4,324 patients, illustrate that modifiable factors directly influence whether a patient meets quality thresholds under value-based reimbursement ^[7]B2b. The clinician should assess these variables preoperatively and track PROMs postoperatively as part of the VBC "vital signs."

Phenotypic Variants: VBC Models in Practice

Value-based care presents in several clinical phenotypes. The most common is the post-acute care patient, often an older adult with cardiovascular or cerebrovascular disease discharged to a skilled nursing facility. These patients benefit from certification programs that standardize geriatric assessments and preventive strategies ^[13]D5. Another variant is the surgical patient under bundled payment, where modifiable factors like TXA use and opioid minimization are actively managed to optimize outcomes and reduce costs. A third is the primary care patient in a capitated model, where chronic disease control (HbA1c, blood pressure) is aggressively targeted to prevent hospitalizations.

Red Flags: Signs of Poor VBC Performance

Certain clinical findings should raise concern that a patient is not benefiting from the VBC model:

• Prolonged length of stay (LOS > 5 days) is associated with a 50% increase in in-hospital complications (OR 1.50) and a 23% increase in 90-day readmissions (OR 1.23) ^[7]B2b.
• Failure to achieve MCID or PASS on PROMs by 6 months post-surgery suggests suboptimal care coordination or unresolved modifiable risk factors.
• High in-hospital opioid use independently predicts failure to achieve meaningful improvement in mental health quality of life (SF-12 MCS MCID) ^[7]B2b.
• Readmission within 30 days of discharge from post-acute care signals a breakdown in transitional care, a key target for VBC improvement ^[13]D5.

Atypical Presentations

Not every patient in a VBC model fits the typical profile. Younger patients undergoing elective surgery for a single joint may have fewer comorbidities and lower baseline risk, yet they still contribute to quality metrics. Their outcomes may be less influenced by modifiable factors like TXA or aspirin, and risk adjustment tools must account for this heterogeneity ^[7]B2b. Similarly, patients with acute, isolated conditions (e.g., hip fracture in a previously healthy adult) may not trigger the chronic disease management focus of VBC, but their post-acute care trajectory still affects system-level performance.

Pearl: When a surgical patient fails to achieve functional improvement by 3 months postoperatively, review modifiable factors, especially opioid use and LOS, before attributing the outcome to patient biology; these are the levers VBC models are designed to pull ^[7]B2b.

The clinical presentation of value-based care models, changes in care patterns, utilization, and patient outcomes, must be systematically measured to confirm alignment with value principles. The diagnostic workup for a value-based care model assesses whether an organization's structure, processes, and outcomes achieve the Triple Aim: improved population health, enhanced patient experience, and reduced per capita cost.

Gold-Standard Diagnostic Framework

No single test defines value-based care model performance; the gold standard is a composite dashboard integrating quality metrics, total cost of care, and patient-reported outcomes over a defined period (e.g., 12 months). Risk adjustment is mandatory to ensure fair comparison across populations.

Quality Measures

Key quality measures tracked in value-based models include:

• Cervical cancer screening (declined 3.8 percentage points in FQHCs from 2019-2020 ^[11]B2b)
• Depression screening (declined 7.0 pp ^[11]B2b)
• Blood pressure control in hypertension (declined 6.5 pp; only 1 of 10 measures returned to 2019 levels by 2021 ^[11]B2b)
• Proportion of days covered (PDC) for statins - target ≥0.80 (mean PDC increased from 0.66 to 0.79 after a pharmacy student outreach program, converting 35% of nonadherent patients to adherence ^[15]C4)

Cost Metrics

Total cost of care is measured per patient per month (PMPM) or per episode. For example, the mean total cost for commercially insured patients with metastatic pancreatic cancer receiving NCCN-recommended therapy was $95,426-$116,325, versus $39,777-$40,390 for Medicare, a 3:1 ratio ^[2]B2b. Post- prostate biopsy sepsis costs ranged from $8,672 to $19,100 per episode ^[16]D5. Bundled payment models require precise episode costing; the Operative Value Index (percent change in NDI per $1000 spent) identified that spine surgery provides the most value for patients with high baseline disability, whereas those with low disability may be inappropriate for bundles ^[19]B2b.

Patient Experience and Function

Patient-reported outcome measures (PROMs) such as the Neck Disability Index (NDI) and quality-of-life instruments assess functional recovery. Clubhouse programs for serious mental illness yielded an estimated $11,374 annual societal cost savings per participant, driven by reduced healthcare utilization and productivity losses ^[18]D5.

Diagnostic Algorithm for Assessing Value-Based Care Model Performance

1. Define the population (attributed lives, episode, or condition).
2. Collect baseline data on quality measures, total cost, and PROMs.
3. Risk-adjust for demographics, comorbidities, and social determinants.
4. Benchmark against national or regional targets (e.g., PDC ≥0.80 ^[15]C4).
5. Identify gaps, e.g., low blood pressure control despite high visit volume.
6. Intervene with targeted quality improvement (e.g., self-measured blood pressure monitoring ^[20]D5, telehealth ^[20]D5, pharmacy outreach ^[15]C4).
7. Re-measure at predefined intervals (e.g., quarterly).

Low-Value Care Detection

Eliminating unnecessary routine labs is a key diagnostic component of efficient care. Following primary total hip arthroplasty, patients with normal preoperative hemoglobin who received tranexamic acid did not benefit from routine postoperative CBCs; no actionable information resulted from these tests ^[14]B2b. In head and neck cancer , the positive surgical margin rate did not differ by hospital type (32.0%-35.0%), but academic centers were more likely to use adjuvant chemoradiation (OR 2.4, 95% CI 1.2-5.0), suggesting potential overuse ^[17]B2b.

High-Yield Pearl: The most actionable diagnostic in value-based care is the gap between current and target performance on a balanced set of measures, no single metric captures the full picture.

Pearl: Risk adjustment is the linchpin of fair value-based care diagnosis: without it, organizations serving complex patients will appear underperformers, leading to misallocation of resources and disincentives for caring for the sickest populations.

Once a diagnosis is established, value-based care models require risk stratification to adjust payments, target care management , and predict resource use. Without accurate risk tiering, providers caring for complex patients may be unfairly penalized under bundled payment or shared-savings programs ^[22]B2b.

Risk Adjustment Tools

Validated comorbidity indices form the backbone of risk stratification. The Charlson Comorbidity Index (CCI) is widely used: octogenarians undergoing total hip arthroplasty (THA) are more likely to have a CCI ≥3 than patients aged 65-69 years (30% vs 17%; OR 2.07, 95%) ^[22]B2b. This higher burden translates into a 21% readmission rate in octogenarians versus 12% in younger patients (OR 1.64, 95%) ^[22]B2b. Payers often use proprietary insurance member risk scores; for THA, these scores show the closest association with total cost and surplus, regardless of insurance type ^[21]B2b. However, agreement between payer-reported comorbidities and institutional records is poor: kappa values range from 0.062 to 0.791 for THA and TKA, with diabetes being the only condition showing strong agreement (κ = 0.791 for THA, 0.768 for TKA) ^[21]B2b. This discordance puts institutions at a disadvantage when negotiating risk-adjusted payments.

Modifiable Risk Factors

Certain perioperative factors that surgeons can influence also affect quality metrics under value-based models. In a cohort of 4,324 TKA patients, tranexamic acid (TXA) use increased the odds of achieving the Knee Injury and Osteoarthritis Outcome Score (KOOS) minimal clinically important difference (MCID) (OR 1.33, P = 0.008) and patient acceptable symptom state (PASS) (OR 1.29, P = 0.020) ^[7]B2b. Conversely, aspirin thromboprophylaxis reduced the odds of achieving KOOS MCID (OR 0.68, P = 0.013) and PASS (OR 0.73, P = 0.040) ^[7]B2b. Length of stay (LOS) was inversely associated with KOOS MCID (OR 0.88, P = 0.002) and PASS (OR 0.81, P < 0.001) but directly associated with in-hospital complications (OR 1.50, P < 0.001) and 90-day readmissions (OR 1.23, P = 0.005) ^[7]B2b. These findings suggest that risk adjustment models should incorporate modifiable variables to incentivize preoperative optimization.

Data Challenges

Risk stratification depends on structured data, yet electronic health records (EHRs) are plagued by fragmentation. Unstructured documentation limits clinical decision support, trial matching, and quality measurement ^[23]D5. Emerging artificial intelligence tools, such as large language models (LLMs), can automate structured data capture while reducing clinician burden ^[23]D5. In a health plan pilot offering quantitative coronary CT angiography (QCCTA) to diabetic members, utilizers had better glycemic control (HbA1c 6.5% vs 7.0%, P = 0.05) and lower 10-year atherosclerotic cardiovascular disease risk (8.5% vs 10.8%, P = 0.07) but higher near-term cardiovascular expenditure ($19.04/month vs $0/month, P < 0.0001) ^[24]B2b. This illustrates that risk stratification must account for both clinical risk and utilization patterns to avoid misaligned incentives.

Controversies and Guideline Disagreement

Pearl: Accurate risk stratification in value-based care requires reconciling payer and provider comorbidity data; relying solely on administrative claims may underestimate patient complexity and unfairly penalize institutions caring for high-risk populations ^{[21]B2b[22]B2b}.

The severity classification and risk-adjusted cost curves described above directly inform the acute management of decompensation episodes. The goal is to match patient acuity to the appropriate care setting while minimizing low-value utilization, reducing readmissions, and preserving functional status.

Step 1: Initial Assessment and Severity Classification

Triage every acute event with a validated risk score (e.g., Hospital Frailty Risk Score, AKI risk index, or the MIPS Value Pathway composite for emergency care ^[27]D5) to determine whether the patient can be managed in an outpatient-enhanced setting, observation unit, or full inpatient bed. For example, in advanced CKD (stages 4-5), an acute rise in serum creatinine without hyperkalemia or severe acidosis may be managed with dietary optimization and keto-analogue supplementation rather than expedited dialysis initiation ^[25]D5. Patients with AKI requiring hospitalization should be stratified by the presence of oliguria, need for vasopressors, and comorbid illness burden ^[8]D5.

Step 2: First-Line Interventions to Avoid Hospitalization or Intensive Care

When clinically safe, initiate protocol-driven care in the lowest-acuity environment. For CKD patients with volume overload and reduced glomerular filtration rate, prescribe loop diuretics (e.g., furosemide 40-80 mg IV) and a very low protein diet (0.3 g/kg/day) supplemented with keto-analogues to reduce uremic symptoms and delay dialysis ^[25]D5 (Level 2b). For acute cardiovascular decompensation, utilize standardized post-acute care pathways that integrate geriatric assessments and guideline-directed medical therapy; the AHA/ASA has endorsed certification programs to standardize this transition ^[13]D5. Pain exacerbations in total joint arthroplasty patients should be managed with multimodal oral analgesics and early physical therapy to avoid emergency department visits; one study found that pre-THA patients using corticosteroid injections and PT had significantly higher costs in the year before surgery, but THA itself reduced costs by at least $250 in the year after ^[28]B3b.

Step 3: Monitoring, Titration, and Avoiding Harmful Practices

Monitor clinical response with point-of-care tools: for AKI, track urine output, serum creatinine Q12h, and avoid nephrotoxins (NSAIDs, aminoglycosides) ^[8]D5. In a value-based framework, also track real-time cost data using time-driven activity-based costing (TDABC) ^[26]C4 to ensure the care intensity is justified by outcomes. Do NOT initiate emergency dialysis solely because of an elevated creatinine in a stable chronic patient; instead, follow the supplemented very-low-protein diet protocol for at least 2 weeks to assess for renal recovery ^[25]D5. For postoperative decompensation after arthroplasty, avoid routine cross-sectional imaging or prolonged opioid prescribing; the evidence shows similar 90-day complications and 1-year patient-reported outcomes between robotic and manual TKA despite longer operative times in the robotic group (113 vs 105 minutes, p<0.001) ^[29]B2b.

Step 4: Transition to Post-Acute Care and Readmission Prevention

Plan discharge from the acute event within 48 hours if the patient is hemodynamically stable and has a clear transition plan. Post-acute care settings should be certified under programs like the AHA/ASA's proposed post-acute certification, which aims to reduce readmission rates through standardized processes ^[13]D5. For AKI survivors, outpatient nephrology follow-up within 7 days is recommended, though evidence for specific care models remains limited ^[8]D5. Black patients in bundled payment programs for TJA have significantly higher emergency department return and hospital readmission rates, indicating that acute management protocols must include culturally tailored discharge instructions and social support assessment to avoid widening disparities ^[30]B3b.

Controversies and Guideline Disagreement

Pearl: In VBC models, the acute management priority is to match patient acuity to the lowest-cost effective care setting, using validated risk stratification, evidence-based nutritional and pharmacological interventions, and early post-acute transition planning to reduce readmissions and preserve residual function.

Once acute episodes are stabilized, value-based care models shift emphasis to long-term disease management and definitive therapies that reduce cumulative downstream costs and improve patient outcomes. This section reviews evidence for chronic disease self-management, nutritional interventions, surgical definitive care, and integrated care models within value-based frameworks.

Chronic Disease Management: Technology-Enabled Self-Management

For chronic conditions such as diabetes, technology-enabled self-management education and support (DSMES) has emerged as a high-value intervention. A systematic review of 25 meta-analyses and reviews found that 18 of 25 reported significant reductions in A1c when programs integrated four essential components: bidirectional communication, use of patient-generated health data, tailored education, and individualized feedback ^[32]B2a (Level 2a). Interventions employing mobile phones and secure messaging were most common. Organizations and payers should consider integrating these digital solutions for population health under value-based models ^[32]B2a.

Nutritional Interventions to Delay Disease Progression

In advanced chronic kidney disease (stages 4-5), nutritional strategies align with value-based goals of delaying dialysis initiation. Low and very low protein diets supplemented with keto-analogues of amino acids reduce nitrogenous waste production, slow CKD progression, and preserve residual kidney function without causing malnutrition ^[25]D5 (Level 5). Meta-analyses suggest these diets prolong dialysis-free periods and improve quality of life, though careful monitoring and patient adherence are critical ^[25]D5. This approach also supports incremental dialysis transition, where supplemented diets continue on non-dialysis days, reducing treatment burden and costs ^[25]D5.

Definitive Surgical Interventions in Value-Based Models

Definitive procedures such as total joint arthroplasty are cost-saving over the longitudinal care cycle. In a cohort of 12,240 primary total hip arthroplasty (THA) patients, post-THA annual claims costs were at least $250 less per patient compared to nonoperative treatment costs in the prior year, across all payer types ^[28]B3b (Level 3b). Policy makers should account for this cost-efficacy when designing value-based bundles for osteoarthritis management ^[28]B3b.

Revision shoulder arthroplasty outcomes also inform value-based models. Revision of reverse shoulder arthroplasty (RSA) to another RSA carries a 32% repeat revision rate versus <14% for other revision categories, often for periprosthetic infection ^[6]B2b (Level 2b). This higher risk should be factored into bundled payment calculations.

In hand and wrist care, cost-effectiveness studies in single-payer systems show that reduced imaging strategies for distal radius fractures and bandaging instead of rigid immobilization are more cost-effective, and immediate MRI for scaphoid fractures outperforms standard care ^[33]B2a (Level 2a). Standardized value assessment methodologies are needed for multi-payer settings ^[33]B2a.

Robotic-assisted total joint arthroplasty incurs higher upfront costs but may offset these through reduced complications, shorter hospital stays, and improved discharge metrics, especially with procedural clustering and experienced teams ^[37]D5 (Level 5). Leasing models and market competition are accelerating adoption, but value remains highly institution-dependent ^[37]D5.

Specialty Medical Homes and Integrated Care

The specialty medical home (SMH) model delivers multidisciplinary, high-quality care for chronic diseases like inflammatory bowel disease (IBD), with early evidence of improved outcomes and reduced expenses ^[36]D5 (Level 5). Similarly, the Kidney Care Choices model (starting 2022) and ESKD Treatment Choices model emphasize nephrologist-led care coordination, home dialysis, and kidney transplantation to improve quality and cost efficiency ^[34]D5 (Level 5). In liver transplantation , value-based models are being explored to improve alcohol use disorder management and reduce relapse, leveraging behavioral and pharmacologic approaches, digital health, and centers of excellence ^[5]D5 (Level 5).

Implementation Challenges

Despite potential savings of up to $1 trillion globally, implementation of value-based healthcare models in cardiology and electrophysiology remains in its infancy, hindered by the need for organizational restructuring, cross-functional teams, guideline adherence tracking, and patient-reported outcome measurement ^[38]B2a (Level 2a). These barriers apply broadly across specialties.

Pearl: Integrating technology-enabled self-management, nutritional interventions to delay disease progression, and definitive procedures like arthroplasty into value-based care models can reduce long-term costs and improve outcomes, but successful implementation requires standardized outcome metrics and institutional infrastructure ^{[32]B2a[28]B3b[25]D5}.

The transition from fee-for-service to value-based care was catalyzed by accumulating evidence that volume-driven reimbursement produced fragmented, costly care with variable outcomes ^[39]D5. Early experiments with capitation in the 1990s demonstrated cost savings but often at the expense of patient access and satisfaction, leading to their partial abandonment. The modern era of value-based care began with the Medicare Modernization Act (2003) and the Affordable Care Act (2010), which introduced accountable care organizations (ACOs), bundled payments, and the Hospital Readmissions Reduction Program.

Landmark Demonstrations and Policy Milestones

The Medicare Shared Savings Program (MSSP), launched in 2012, remains the largest ACO initiative, with over 500 participating organizations. The Bundled Payments for Care Improvement (BPCI) initiative tested episode-based payments for conditions such as joint replacement and congestive heart failure. These demonstrations showed that aligning financial incentives with quality metrics could reduce costs without harming outcomes, though savings were modest (1-2% per episode) ^[13]D5. The Comprehensive Care for Joint Replacement (CJR) model, mandatory in 67 metropolitan areas, required hospitals to be accountable for the entire 90-day episode, including post-acute care. This model reduced average episode payments by $1,066 per case (3.6%) while maintaining or improving complication rates ^[7]B2b.

Lessons from Abandoned Approaches

Pure capitation, where providers assume full financial risk for a population, was largely abandoned because it encouraged underuse of necessary services and destabilized safety-net providers. Similarly, early pay-for-performance programs that tied small bonuses to process measures (e.g., mammography rates) failed to improve outcomes and were replaced by models that reward outcomes and patient experience. The shift toward patient-reported outcome measures (PROMs) and experience measures (PREMs) represents the latest evolution, as seen in the integration of digital platforms for real-time monitoring after robot-assisted radical prostatectomy , where 86% of patients completed questionnaires at 6 weeks and satisfaction scores were high (median 9-10) ^[40]B3b.

Current Standard and Future Directions

The current standard of value-based care emphasizes holistic, patient-centric models that address medical, behavioral, and social needs. In inflammatory bowel disease, the "360 IBD Care" model incorporates multidisciplinary teams, digital tools, and payor alignment to improve both disease-specific outcomes and general well-being ^[39]D5. Certification programs, such as those proposed by the American Heart Association for post-acute cardiovascular care, aim to standardize evidence-based processes and reduce readmission rates ^[13]D5. The evidence from total knee arthroplasty demonstrates that modifiable perioperative factors, tranexamic acid use, avoidance of opioids, shorter length of stay, can significantly improve quality metric thresholds, informing risk adjustment tools for alternative payment models ^[7]B2b.

Pearl: The evolution of value-based care shows that payment reform must be paired with robust quality measurement, risk adjustment, and patient engagement tools; models that ignore any of these components have been abandoned or failed to scale.

As reimbursement models evolved from volume to value, the general internist’s diagnostic reasoning became a central lever for both cost efficiency and quality improvement. Managing undifferentiated symptoms under genuine uncertainty is a core cognitive task that, when performed methodically, reduces wasteful testing and inappropriate specialist referrals. Value-based care models reward precisely this skill by tying payment to outcomes rather than services rendered.

Diagnostic Uncertainty as a Driver of Resource Use

Every undifferentiated symptom, chest pain, dyspnea, joint pain, carries a differential diagnosis of widely varying pretest probability. The generalist’s job is to narrow that list using history, physical examination, and point-of-care scores before ordering expensive or invasive tests. In value-based systems, failing to do so inflates costs without improving outcomes. For example, referral to pulmonary rehabilitation after COPD hospitalization is proven to reduce readmissions and save costs, yet remains underutilized because primary care providers and hospitalists do not consistently identify eligible patients ^[41]D5. Embedding validated decision rules (e.g., COPD exacerbation risk scores) into the generalist’s workflow can close that gap.

Point-of-Care Scores Sharpen Probability

Clinical prediction rules, the Wells criteria for venous thromboembolism, CURB-65 for pneumonia, HEART score for chest pain, are the generalist’s most practical tools for risk-stratifying undifferentiated presentations. In a value-based framework, using these scores to classify patients as low, moderate, or high probability directly guides the decision to test, treat, or refer. Low-probability patients can often be managed without advanced imaging or specialist consultation, avoiding the harms of overdiagnosis and the costs of unnecessary workups. The shift toward value-based radiology models, including second-opinion and concierge services, reinforces this principle by emphasizing appropriateness criteria and communication between referring clinicians and radiologists ^[42]D5.

Setting Explicit Referral Thresholds

Value-based care demands that referrals to specialists or subspecialty programs occur only when evidence supports a meaningful change in management . The generalist sets the threshold: for example, referring a patient with hip or knee osteoarthritis to a physical therapist-led comprehensive program (such as the Joint Health Program) instead of directly to an orthopedic surgeon. That program uses shared decision-making, cognitive-behavioral strategies, and multidisciplinary coordination to avoid unnecessary surgery, reduce costs, and improve patient engagement ^[43]C4. Similarly, the generalist’s decision to refer for pulmonary rehabilitation should be triggered by a COPD hospitalization and objective exercise limitation, not by generic dyspnea ^[41]D5.

Diagnostic Stewardship in the Value-Based Era

The generalist is the gatekeeper of appropriate resource utilization. By owning the diagnostic reasoning process, applying point-of-care scores, documenting pretest probability, and consulting evidence-based referral thresholds, the internist directly supports the triple aim of better outcomes, lower costs, and improved patient experience. This cognitive work, often invisible in fee-for-service billing, becomes a recognized driver of value when capitated or bundled payments reward efficient, accurate diagnosis.

Pearl: The generalist’s disciplined application of a single validated clinical prediction rule for an undifferentiated symptom is the highest-value step in the diagnostic cascade, it determines whether the next test or referral adds or subtracts value.

The shift to value-based care (VBC) introduces its own profile of system-level complications that providers must anticipate and mitigate. These include unintended disparities in access, imperfect risk adjustment, and complications arising from care pathways designed to optimize efficiency but which may produce new failure modes.

Volume-Outcome Relationships and Centralization

High-volume centers consistently achieve lower complication rates for complex procedures. For esophagectomy , hospitals performing at least 20 annual cases (high-volume hospitals, HVHs) had significantly lower in-hospital mortality (AOR 0.65), pneumonia (AOR 0.69), prolonged ventilation (AOR 0.50), sepsis (AOR 0.80), and tracheostomy (AOR 0.66) compared with low-volume hospitals (LVHs) ^[12]B2b. However, HVH status paradoxically increased the odds of nonhome discharge (AOR 1.56, P<0.01), a metric that may penalize VBC programs focused on episode-of-care costs ^[12]B2b. Similarly, spine centers of excellence that meet The Joint Commission Advanced Certification requirements reduce complications through standardized preoperative optimization and coordinated postoperative care, but their implementation requires rigorous program evaluation and stakeholder alignment ^[10]D5.

Risk Adjustment Disparities and Access Penalties

Accurate risk stratification is the backbone of fair VBC reimbursement, yet payer and institutional comorbidity records disagree substantially. Kappa values for conditions such as hypertension ranged from 0.139 to 0.791 for total hip arthroplasty (THA) and 0.062 to 0.768 for total knee arthroplasty (TKA), with diabetes the only condition showing strong agreement (k=0.791 for THA, 0.768 for TKA) ^[21]B2b. Such discrepancies place institutions at a disadvantage when risk adjustment tools fail to capture true patient complexity, potentially reducing participation in care for sicker patients.

Octogenarians undergoing primary THA illustrate the tension between VBC incentives and vulnerable populations. Compared with patients aged 65-69 years, octogenarians had higher Charlson scores ≥3 (30% vs 17%; OR 2.07 [1.98-2.20]) and were more likely to have coronary artery disease or congestive heart failure (47% vs 29%; OR 2.16 [2.06-2.26]) ^[22]B2b. Their risk of dislocation was +12%, venous thromboembolism (VTE) +14%, and mortality +150%, and 21% were readmitted within 90 days vs 12% in the younger group (OR 1.64 [1.54-1.75]; p<0.001) ^[22]B2b. Because VBC models penalize readmissions and complications, these data suggest that, without appropriate risk adjustment, octogenarians may face reduced access to elective arthroplasty under accountable care arrangements.

Modifiable Perioperative Factors and Quality Metric Attainment

Surgeon-influenced factors can dramatically affect outcomes and should be optimized within VBC frameworks. The use of tranexamic acid (TXA) was associated with higher odds of achieving the Knee Injury and Osteoarthritis Outcome Score (KOOS) minimal clinically important difference (MCID) (OR 1.33, P=0.008) and patient acceptable symptom state (PASS) (OR 1.29, P=0.020), while aspirin thromboprophylaxis was associated with lower odds of reaching these thresholds (OR 0.68 and OR 0.73, respectively) ^[7]B2b. Length of stay (LOS) was directly associated with in-hospital complications (OR 1.50, P<0.001) and 90-day readmissions (OR 1.23, P=0.005), but longer LOS also increased odds of home discharge (OR 2.5, P≤0.001), creating a tension within bundled payments ^[7]B2b. In-hospital opioid use independently predicted failure to achieve the SF-12 Mental Component Summary MCID (OR 0.56, P=0.006), emphasizing the need for multimodal analgesia ^[7]B2b.

Technology Implementation: Robotic Assistance

Robotic-assisted total joint arthroplasty (RA-TJA) is projected to account for 70% of arthroplasties by 2030, yet its value depends on institutional context ^[37]D5. While RA-TKA demonstrates shorter LOS (0.48 vs 1.2 days) and higher home discharge rates, it also involves longer operative time (113 vs 105 minutes) and more physical therapy visits (11.5 vs 10.0 median), with similar complication rates and 1-year patient-reported outcomes ^[29]B2b. The upfront costs of robotic platforms may be offset by reduced complications and shorter stays, but only when paired with procedural clustering and experienced teams; without these, VBC programs may absorb higher costs without proportional benefit ^[37]D5.

Temporal Trends in Complication Profiles

Over a decade (2011-2020), distal radius fracture open reduction and internal fixation (ORIF) showed improving readmission and revision rates but a rising trend in superficial surgical site infections, even as patient comorbidities and wound classification worsened ^[1]B2b. This signals that VBC quality measures must be continuously updated to capture new failure modes that may emerge as case mix shifts and care pathways evolve.

Complication Table

Pearl: The complication most likely to erode the financial sustainability of a VBC program is the risk-adjustment blind spot, when payer databases miss comorbidities present in institutional records, the penalty for caring for complex patients (e.g., octogenarians, multiple comorbidities) falls on the provider ^{[21]B2b[22]B2b}. Proactively reconciling comorbidity records with payers and implementing surgeon-influenced optimizations (TXA, multimodal analgesia, early mobilization) are actionable steps to align clinical quality with financial viability.

Complications, such as revision surgery, infection, or readmission, fundamentally shape the trajectory of patients and the economic sustainability of healthcare delivery. Value-based care models aim to alter this natural history by aligning incentives with outcomes and efficiency, offering a prognosis distinct from the fee-for-service baseline.

Trajectory Under Fee-for-Service vs. Value-Based Models

Untreated (fee-for-service) systems exhibit high variability in outcomes and costs. For shoulder arthroplasty, minimum clinically important difference (MCID) thresholds vary widely (American Shoulder and Elbow Surgeons score: 6.3-29.5; Constant: -0.3 to 12.8) ^[44]B2a, signaling inconsistent patient-perceived value. Revision shoulder arthroplasty carries a repeat revision rate up to 32% when reverse-to-reverse constructs fail, often for infection ^[6]B2b. In lumbar fusion, less-experienced surgeons (<15 years) incur higher mean intraoperative costs ($22,259.71 vs. $16,071.78, p<0.001) with lower operative value ^[45]B3b.

In contrast, value-based interventions reshape this natural history. Technology-enabled diabetes self- management , incorporating two-way communication, patient-generated data, tailored education, and feedback, reduces A1c across 18 of 25 reviews ^[32]B2a. Cosurgeon approaches for breast microsurgery shorten length of stay (2.4 vs. 3.1 days) and reduce total cost from $31,758 to $25,160 (p<0.01), turning a negative margin (-$6255) into a positive one ($1099) ^[46]B3b. These gains parallel those seen with robotic-assisted arthroplasty, where higher upfront costs are offset by fewer complications and shorter stays, though value remains institution-dependent ^[37]D5.

Prognostic Factors for Success

Surgeon experience and case volume are critical. Surgeons with ≥15 years of experience or ≥100 annual lumbar fusions achieve greater Oswestry Disability Index improvement (34.90 vs. 22.07) and higher Operative Value Index scores (2.22 vs. 1.01) ^[45]B3b. Similarly, pediatric observation units, though heterogeneous in reporting, demonstrate potential for efficient care when standard outcome measures are applied ^[31]B2a.

The Need for Standardization

Without uniform metrics, the natural history of value-based models remains difficult to track. MCID variability across shoulder arthroplasty studies ^[44]B2a and inconsistent length-of-stay definitions in pediatric observation ^[31]B2a highlight this gap. Ongoing multicenter trials and standardized outcome reporting are essential to define the true prognosis for populations transitioning to value-based care ^[37]D5.

Pearl: Without uniform outcome reporting, the natural history of value-based models remains poorly characterized, limiting generalizability.

Prognosis varies substantially across patient subgroups, and value-based care models must account for these differences to avoid penalizing hospitals caring for high-risk populations. Two groups, frail older adults and dual-eligible beneficiaries, illustrate the critical need for risk adjustment and integrated care design.

Elderly and Frail Older Adults

Octogenarians undergoing primary total hip arthroplasty (THA) have a comorbidity burden that is not reflected in standard risk‑adjustment models for bundled‑care programs ^[22]B2b. Compared with patients aged 65-69 years, octogenarians are more likely to have a Charlson comorbidity score ≥3 (30% vs 17%) and to carry diagnoses of coronary artery disease or congestive heart failure (47% vs 29%) ^[22]B2b. These factors translate into higher postoperative complication rates: risk of dislocation is increased by 12%, venous thromboembolism by 14%, and mortality by 150% ^[22]B2b. Readmission within 30 days occurs in 21% of octogenarians versus 12% of the younger cohort (odds ratio not reported from abstract) ^[22]B2b. Under value‑based payment models that penalize hospitals for readmissions and complications, this vulnerable population may lose access to elective surgery if adjustments are not made ^[22]B2b.

Dual-Eligible and Disabled Populations

Approximately one in five Medicaid beneficiaries is dually enrolled in Medicare, and this group has disproportionately high medical needs and fragmented care ^[47]D5. Nearly half of full‑benefit dual‑eligible individuals qualify for Medicare due to disability, and about one‑third lose full Medicaid benefits during a given year, with 65% of those losses occurring in beneficiaries under age 65 ^[47]D5. Unstable enrollment and the absence of integrated Medicare‑Medicaid administration contribute to suboptimal health outcomes and care experiences ^[47]D5. As Medicaid transforms to value‑based models, strategies must address the diversity within the dual‑eligible population, across race, disability, geography, and health care needs, to improve equity and avoid exacerbating disparities ^[47]D5.

For other special populations, pediatrics, pregnancy, and immunocompromised patients, no specific evidence from value‑based care analyses was identified in the available literature. Future model designs should incorporate risk stratification for these groups to prevent unintended access barriers.

Pearl: When designing risk‑adjustment for value‑based payments, include octogenarian status and dual‑eligibility as covariates; failure to do so may penalize hospitals serving the most complex patients and reduce access to elective surgery ^[22]B2b.

Building on the tailored approaches needed in special populations, the population-health framework of value-based care models mandates systematic prevention, screening, and health maintenance as core strategies to improve outcomes and reduce costs.

Screening and Measurement-Based Care

Value-based care models emphasize adherence to evidence-based screening guidelines, such as USPSTF Grade A and B recommendations. Measurement-based care (MBC), the repeated use of validated symptom measures for screening and treatment guidance, has been shown to improve outcomes for depression compared with usual care and aligns directly with value-based payment structures ^[9]D5. Despite these benefits, population-level screening rates remain fragile. During the COVID-19 pandemic, federally qualified health centers (FQHCs) saw statistically significant declines in cervical cancer screening (-3.8 percentage points [pp]; 95% CI, -4.3 to -3.2 pp), depression screening (-7.0 pp; 95% CI, -8.0 to -5.9 pp), and blood pressure control in hypertension (-6.5 pp; 95% CI, -7.0 to -6.0 pp) from 2019 to 2020; most measures did not return to prepandemic levels by 2021 ^[11]B2b. These findings underscore the need for robust screening infrastructure and catch-up strategies within value-based contracts.

Immunizations and Preventive Services

Immunization visits declined sharply during the pandemic (incidence rate ratio 0.76; 95% CI, 0.73-0.78) and many remained below baseline in 2021 ^[11]B2b. Value-based models should prioritize vaccine delivery through reminder systems, standing orders, and community partnerships. Post-acute care settings, which serve older adults with cardiovascular or cerebrovascular disease, offer an additional opportunity for preventive strategies including immunization and standardized geriatric assessments ^[13]D5. Certification programs in post-acute care could strengthen patient engagement in prevention and wellness ^[13]D5.

Screening for Social Determinants of Health

Social determinants of health (SDOH) have a greater impact on health outcomes than clinical care, and addressing them is essential for success in value-based models ^[48]C4. Primary care has increased screening for SDOH to meet patient needs; integrating such screening into routine health maintenance allows practices to identify barriers to care, such as food insecurity, housing instability, and transportation, and connect patients to community resources ^[48]C4.

Secondary Prevention and Care Transitions

Post-acute care is often siloed, creating gaps in secondary prevention after cardiovascular events or stroke. The American Heart Association/American Stroke Association is developing certification programs to ensure consistent application of guideline-directed preventive therapies, including antiplatelet agents, statins , blood pressure control, and lifestyle counseling ^[13]D5. Embedding preventive strategies into transitional care models reduces readmissions and aligns with value-based incentives.

Pearl: The pandemic revealed that preventive screening and immunizations are highly sensitive to disruptions in care delivery; value-based models must build resilience through registry-based recall, telehealth integration, and community outreach to maintain population coverage ^[11]B2b.